Clinical Trial Update: Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates trastuzumab in combination with serplulimab and chemotherapy for HER2-overexpressing unresectable locally advanced or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Urothelial Carcinoma

Drugs mentioned

• Serplulimab (serplulimab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Xiujuan Qu | Conditions: Urothelial Carcinoma, Biliary Tract Cancer | Phase 2 | Status: RECRUITING